A major pharmaceutical acquisition was announced Tuesday as British company GSK revealed plans to purchase American cancer drug developer Nuvalent in a transaction valued at $10.6 billion.
The deal involves the UK-based drugmaker acquiring the U.S.-listed company that specializes in developing cancer treatments.
